ESMO WCGIC 2021 | Treating CRC with regorafenib in Latin America

Juan Manuel O’Connor, MD, Institute Alexander Fleming, Buenos Aires, Argentina, discusses optimizing regorafenib dosing in colorectal cancer from a Latin American perspective. Many advances in first- and second- line treatments, as well as reatments for refractory colorectal cancer have been made in recent years. Data from the randomized, phase II ReDOS trial (NCT02368886) has demonstrated that a lower dose of regorafenib, a receptor tyrosine kinase (RTK) inhibitor was well tolerated in patients. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.